home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

28.96 -2.48 (-7.89%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Where Travere Therapeutics Stands With Analysts ↗

December 05, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

November 22, 2022

During Tuesday's trading, 160 companies set new 52-week lows.

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 16, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

November 15, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Recap: Travere Therapeutics Q3 Earnings ↗

October 27, 2022

Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

Travere Therapeutics to Present at Upcoming Investor Conferences

November 09, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Earnings Perspective: Return On Capital Employed ↗

November 03, 2022

Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Travere Therapeutics Reports Third Quarter 2022 Financial Results

October 27, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA ↗

October 14, 2022

Via Benzinga

Expert Ratings for Travere Therapeutics ↗

October 14, 2022

Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:

Via Benzinga

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease ↗

October 14, 2022

Via Benzinga

Travere Therapeutics Return On Capital Employed Overview ↗

August 15, 2022

Via Benzinga

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

October 26, 2022

Data support the Company’s lead investigational product candidate sparsentan

From Travere Therapeutics, Inc.

Via GlobeNewswire

Earnings Outlook For Travere Therapeutics ↗

October 26, 2022

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Travere Therapeutics to Report Third Quarter 2022 Financial Results

October 20, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

October 13, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Recap: Travere Therapeutics Q2 Earnings ↗

August 04, 2022

Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement.

Via Benzinga

Where Travere Therapeutics Stands With Analysts ↗

July 26, 2022

Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter:

Via Benzinga

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 11, 2022

From Travere Therapeutics, Inc.

Via GlobeNewswire

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗

October 05, 2022

Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks.

Via InvestorPlace

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 22, 2022

Via Benzinga

Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗

August 22, 2022

Via Benzinga

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication ↗

August 04, 2022

Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 03, 2022

Gainers

Via Benzinga

4 Analysts Have This to Say About Travere Therapeutics ↗

July 26, 2022

Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 17, 2022

Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com